CIBC Asset Management Inc increased its holdings in shares of Humana Inc (NYSE:HUM) by 7.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,627 shares of the insurance provider’s stock after purchasing an additional 1,085 shares during the quarter. CIBC Asset Management Inc’s holdings in Humana were worth $4,423,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of HUM. Norges Bank acquired a new stake in shares of Humana during the 4th quarter worth about $402,117,000. Millennium Management LLC grew its position in Humana by 254.8% in the 4th quarter. Millennium Management LLC now owns 503,066 shares of the insurance provider’s stock valued at $144,118,000 after acquiring an additional 361,263 shares in the last quarter. Ceredex Value Advisors LLC grew its position in Humana by 53.2% in the 4th quarter. Ceredex Value Advisors LLC now owns 726,423 shares of the insurance provider’s stock valued at $208,468,000 after acquiring an additional 252,341 shares in the last quarter. Morgan Stanley grew its position in Humana by 130.5% in the 3rd quarter. Morgan Stanley now owns 368,401 shares of the insurance provider’s stock valued at $124,712,000 after acquiring an additional 208,595 shares in the last quarter. Finally, Calamos Advisors LLC grew its position in Humana by 114.4% in the 1st quarter. Calamos Advisors LLC now owns 306,086 shares of the insurance provider’s stock valued at $81,419,000 after acquiring an additional 163,339 shares in the last quarter. 94.72% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have weighed in on HUM shares. Credit Suisse Group dropped their target price on Humana from $390.00 to $352.00 and set an “outperform” rating for the company in a research report on Thursday, February 7th. Citigroup dropped their target price on Humana from $397.00 to $362.00 and set a “buy” rating for the company in a research report on Thursday, February 7th. Zacks Investment Research downgraded Humana from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. ValuEngine downgraded Humana from a “hold” rating to a “sell” rating in a research report on Thursday, April 11th. Finally, Barclays dropped their target price on Humana from $351.00 to $327.00 and set an “overweight” rating for the company in a research report on Wednesday, April 17th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $337.26.
In other news, insider Roy A. Beveridge sold 8,278 shares of Humana stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $307.16, for a total value of $2,542,670.48. Following the completion of the transaction, the insider now owns 12,409 shares in the company, valued at approximately $3,811,548.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher H. Hunter sold 15,586 shares of Humana stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $305.24, for a total value of $4,757,470.64. Following the completion of the transaction, the insider now owns 28,100 shares of the company’s stock, valued at approximately $8,577,244. The disclosure for this sale can be found here. Company insiders own 0.54% of the company’s stock.
Shares of HUM opened at $242.22 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.65 and a quick ratio of 1.65. The stock has a market capitalization of $32.91 billion, a PE ratio of 15.55, a P/E/G ratio of 1.00 and a beta of 0.88. Humana Inc has a 1 year low of $225.65 and a 1 year high of $355.88.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, May 1st. The insurance provider reported $4.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.30 by $0.18. The business had revenue of $16.11 billion during the quarter, compared to analysts’ expectations of $15.67 billion. Humana had a return on equity of 20.77% and a net margin of 2.99%. The business’s quarterly revenue was up 12.8% compared to the same quarter last year. During the same quarter last year, the business posted $3.36 EPS. As a group, sell-side analysts expect that Humana Inc will post 17.57 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend is Thursday, June 27th. Humana’s payout ratio is presently 15.12%.
WARNING: This article was first reported by Stock Observer and is the property of of Stock Observer. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thestockobserver.com/2019/05/17/humana-inc-hum-position-increased-by-cibc-asset-management-inc.html.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Story: How is Preferred Stock Different from Common Stock?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.